BioMarin Pharmaceutical Inc.

LSE:0HNC.LHealthcare

——At close · Market cap — · Next earnings Mon 26 Oct

USD billions	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	YoY
Revenue	1.8	1.8	2.0	2.4	2.8	3.2	+13.5%
Cost of revenue	0.6	0.5	0.5	1.3	0.6	0.7	+18.2%
Gross profit	1.3	1.3	1.5	1.2	2.2	2.5	+12.1%
Research & development	0.6	0.6	0.6	0.7	0.7	0.9	+23.4%
Selling, general & administrative	0.7	0.8	0.8	0.9	0.9	1.0	+9.6%
Selling & marketing	0.0	0.0	0.0	0.0	0.0	0.0	−100.0%
Operating expenses	1.4	1.4	1.5	1.0	1.7	2.0	+15.7%
Operating income	(0.1)	(0.1)	0.0	0.2	0.5	0.5	+0.7%
Interest expense	0.0	0.0	0.0	0.0	0.0	0.0	−14.0%
Interest income	0.0	0.0	0.0	0.1	0.1	0.1	+0.0%
Other income / expense	0.1	(0.0)	0.1	0.0	0.0	(0.1)	−526.4%
Pre-tax income	(0.0)	(0.1)	0.1	0.2	0.5	0.5	−10.9%
Income tax	(0.9)	(0.0)	0.0	0.0	0.1	0.1	+16.3%
Net income	0.9	(0.1)	0.1	0.2	0.4	0.3	−18.3%
Discontinued operations	0.0	0.0	0.0	0.0	0.0	0.0	—
Other net income adjustments	0.0	0.0	0.0	0.0	0.0	0.0	—
EPS, basic (per share)	4.75	(0.35)	0.76	0.89	2.25	1.82	−19.1%
EPS, diluted (per share)	4.53	(0.35)	0.75	0.88	2.21	1.80	−18.6%
EBITDA	0.0	0.0	0.2	0.3	0.7	0.6	−5.8%
Depreciation & amortization	0.1	0.1	0.1	0.1	0.1	0.1	−17.5%
Weighted average shares (shares)	180,804,000	182,852,000	185,266,000	187,834,000	190,027,000	191,787,000	+0.9%
Weighted average diluted shares (shares)	191,678,000	182,852,000	188,963,000	191,595,000	196,708,000	197,394,000	+0.3%
Gross margin	68.2%	71.2%	73.3%	47.8%	78.0%	77.1%	−0.9 pts
Operating margin	−5.7%	−3.9%	0.4%	6.5%	18.7%	16.6%	−2.1 pts
Net margin	46.6%	−3.5%	6.9%	6.9%	15.0%	10.8%	−4.2 pts

USD billionsUpdated Tue 31 Mar ·

ⓘ

Amounts are shown in the stated units; per-share amounts and shares are unscaled. Negative amounts are in brackets.